About PILA PHARMA
PILA PHARMA is a privately held clinical stage pharmaceutical company based in Malmö, Sweden.
PILA PHARMA is developing a novel type of oral anti-diabetic agent: a TRPV1 antagonist for the treatment of diabetes.
PILA PHARMA owns issued use-patents giving the right to treat diabetes and obesity with TRPV1 antagonists. In addition, the company owns a specific, potent and clinical safe small-molecule TRPV1-angagonist, XEN-D0501.
XEN-D0501, is currently being investigated in type-2 diabetic patients for its safety following a single oral dose (trial PP-CT01, dosing completed) and for its safety and efficacy following 28 days oral dosing (trial PP-CT02, approved/ to be initiated).
Nytt piller skal göra livet lättare för diabetiker – svensk bolag vill förändra sjukvården.
An interview with CEO Dorte X. Gram published in Veckans Affärer, Sweden.
Winning prize to PILA PHARMA at the Almi Invest pitch competition 2016, sponsored by Veckans Affärer.
Check out the resulting article here
Uppstickaren som vill ta plats i läkemedelsindustrin.
An interview with CEO Dorte X. Gram published in ‘DI Almedalen, Distributed with Dagens Industri, Sweden.
Read the article in Swedish here